Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy.
Nishimura T, Yamaguchi K, Hashimoto H, Niimi T, Yokomizo C, Fujii H, Minami M, Sakamoto M, Ohnish N, Nagao Y, Okita M, Umemura A, Shima T, Okanoue T, Itoh Y. Nishimura T, et al. Among authors: yokomizo c. Hepatol Res. 2012 Oct;42(10):966-73. doi: 10.1111/j.1872-034X.2012.01016.x. Epub 2012 May 1. Hepatol Res. 2012. PMID: 22548706
Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads.
Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, Fujii H, Minami M, Yasui K, Mitsuyoshi H, Okanoue T, Takehara T, Hiasa Y, Onji M, Yoshikawa T. Itoh Y, et al. Among authors: yokomizo c. Hepatol Res. 2011 Feb;41(2):126-32. doi: 10.1111/j.1872-034X.2010.00750.x. Hepatol Res. 2011. PMID: 21269382
Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy.
Itoh Y, Nishimura T, Yamaguchi K, Yokomizo C, Fujii H, Minami M, Nagao Y, Sumida Y, Hashimoto H, Umemura A, Shima T, Okanoue T, Yoshikawa T. Itoh Y, et al. Among authors: yokomizo c. Hepatol Res. 2011 Dec;41(12):1145-52. doi: 10.1111/j.1872-034X.2011.00886.x. Epub 2011 Sep 26. Hepatol Res. 2011. PMID: 21951359
Prediction of a favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study.
Nishimura T, Yamaguchi K, Fujii H, Okada Y, Yokomizo C, Niimi T, Sumida Y, Yasui K, Mitsuyoshi H, Minami M, Umemura A, Shima T, Okanoue T, Itoh Y. Nishimura T, et al. Among authors: yokomizo c. Hepatol Res. 2013 May;43(5):557-62. doi: 10.1111/j.1872-034X.2012.01091.x. Epub 2012 Sep 14. Hepatol Res. 2013. PMID: 22978477
[Treatment of difficult-to-treat chronic hepatitis B].
Itoh Y, Yamaguchi K, Nishimura T, Yokomizo C, Yoshikawa T. Itoh Y, et al. Among authors: yokomizo c. Nihon Rinsho. 2011 May;69 Suppl 4:507-11. Nihon Rinsho. 2011. PMID: 22096970 Review. Japanese. No abstract available.
Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.
Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Fujii H, et al. Among authors: yokomizo c. World J Hepatol. 2015 Dec 8;7(28):2841-8. doi: 10.4254/wjh.v7.i28.2841. World J Hepatol. 2015. PMID: 26668696 Free PMC article.
25 results